Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
株式のランク #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
株価
$8.16
最終同期: 2025-06-26
時価総額
$234.57M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Regulus Therapeutics Inc. (RGLS)

カテゴリー

Regulus Therapeutics Inc.(RGLS)の発行済株式数
March 2025 時点の発行済株式数 66.17M
Regulus Therapeutics Inc. の最新の財務報告および株価によると、現在の発行済株式数は 66.17M です。December 2023 の終わりには、同社は 18.96M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Regulus Therapeutics Inc.(RGLS)の発行済株式数の履歴(2010 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 66.17M 17.44%
2024 56.35M 197.18%
2023 18.96M 24.25%
2022 15.26M 78.05%
2021 8.57M 145.03%
2020 3.50M 102.65%
2019 1.73M 97.97%
2018 871.86K 0.61%
2017 866.58K 96.90%
2016 440.11K 2.73%
2015 428.43K 16.61%
2014 367.42K 14.58%
2013 320.66K 368.55%
2012 68.44K 3,099.49%
2011 2.14K 0.00%
2010 2.14K 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M 283.68%
US
62.19M -6.03%
NL
396.00M 498.42%
US
478.91M 623.71%
AU
- -
CH